Online citations, reference lists, and bibliographies.
← Back to Search

Adjuvant Trastuzumab In HER2-positive Breast Cancer.

D. Slamon, W. Eiermann, N. Robert, T. Pieńkowski, M. Martín, M. Press, J. Mackey, J. Glaspy, Arlene Chan, M. Pawlicki, Tamás Pintér, V. Valero, M. Liu, G. Sauter, G. von Minckwitz, F. Visco, V. Bée, M. Buyse, B. Bendahmane, I. Tabah-Fisch, M. Lindsay, A. Riva, J. Crown
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
BACKGROUND Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab. METHODS We randomly assigned 3222 women with HER2-positive early-stage breast cancer to receive doxorubicin and cyclophosphamide followed by docetaxel every 3 weeks (AC-T), the same regimen plus 52 weeks of trastuzumab (AC-T plus trastuzumab), or docetaxel and carboplatin plus 52 weeks of trastuzumab (TCH). The primary study end point was disease-free survival. Secondary end points were overall survival and safety. RESULTS At a median follow-up of 65 months, 656 events triggered this protocol-specified analysis. The estimated disease-free survival rates at 5 years were 75% among patients receiving AC-T, 84% among those receiving AC-T plus trastuzumab, and 81% among those receiving TCH. Estimated rates of overall survival were 87%, 92%, and 91%, respectively. No significant differences in efficacy (disease-free or overall survival) were found between the two trastuzumab regimens, whereas both were superior to AC-T. The rates of congestive heart failure and cardiac dysfunction were significantly higher in the group receiving AC-T plus trastuzumab than in the TCH group (P<0.001). Eight cases of acute leukemia were reported: seven in the groups receiving the anthracycline-based regimens and one in the TCH group subsequent to receiving an anthracycline outside the study. CONCLUSIONS The addition of 1 year of adjuvant trastuzumab significantly improved disease-free and overall survival among women with HER2-positive breast cancer. The risk-benefit ratio favored the nonanthracycline TCH regimen over AC-T plus trastuzumab, given its similar efficacy, fewer acute toxic effects, and lower risks of cardiotoxicity and leukemia. (Funded by Sanofi-Aventis and Genentech; BCIRG-006 number, NCT00021255.).
This paper references
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
H. Joensuu (2006)
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 The New England
MJ Arboleda (2013)
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
J. Rossouw (2002)
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.
M. Arboleda (2003)
Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
M. Pinder (2007)
ErbB receptors and cell polarity: new pathways and paradigms for understanding cell migration and invasion.
Michael E Feigin (2009)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
E. H. Romond (2005)
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
E. Tan-chiu (2005)
Tumour biology: Herceptin acts as an anti-angiogenic cocktail
Yotaro Izumi (2002)
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.
R. Pietras (1995)
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
C. Benz (2005)
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
M. Pegram (2004)
Re: Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
F. O'Malley (2009)
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
M. Press (2011)
Polychemotherapy for early breast cancer: an overview of the randomised trials
M. Clarke (1998)
c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.
H. Muss (1994)
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
D. Slamon (1989)
Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
F. O'Malley (2009)
Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study.
J. Doyle (2005)
Humanization of an anti-p185HER2 antibody for human cancer therapy.
P. Carter (1992)
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
N. Robert (2006)
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.
S. Swain (2010)
erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.
S. Paik (1998)
A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines.
M. C. Hancock (1991)
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
M. Pegram (1999)
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
L. Dressler (2005)
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.
D. Tripathy (2004)
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft Dw (1976)
Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis.
V. Van Belle (2010)
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
J. (2002)
The value of TOP2A, EZH2 and paxillin expression as markers of aggressive breast cancer: relationship with other prognostic factors.
D. Panousis (2011)
Untangling the ErbB signalling network
Y. Yarden (2001)
Polychemotherapy for early breast cancer: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group (1998)
Final Study Report (FSR) for H0407g: A Phase 1 safety and tolerance study of intravenous anti-p185 HER2 humanized monoclonal antibody (rhu MAb HER2) in patients with HER2 overexpressing tumors
Slamon (1996)
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
hibitory effects of combinations of HER - 2 / neu antibody and chemotherapeutic agents used for treatment of human breast cancers
M Pegram (1999)
Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers.
D. J. Slamon (2009)
Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
D. Hershman (2007)
Amenorrhea from breast cancer therapy--not a matter of dose.
S. Swain (2010)
Carboplatin Dosing in Ovarian Cancer: Problems and Pitfalls
I. Collins (2011)
Signal Transduction in Transgenic Mouse Models of Human Breast Cancer—Implications for Human Breast Cancer
R. Marcotte (2008)
The role of the EGFR signaling in tumor microenvironment
A. de Luca (2008)
The care transitions intervention: results of a randomized controlled trial.
E. Coleman (2006)
HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15.
S. Paik (2000)
Effects of care coordination on hospitalization, quality of care, and health care expenditures among Medicare beneficiaries: 15 randomized trials.
Deborah Peikes (2009)
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
I. Smith (2007)
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
A. Gennari (2008)
BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)
M. Pegram (2007)
p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.
R. Hudziak (1989)
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
R. Pietras (1994)
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 The New England Journal of Medicine Downloaded from at HKU Libraries on March 21, 2018
MJ Arboleda (2011)
Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling
Qing-Bai She (2008)
HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
K. Pritchard (2006)
Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity.
M. Pegram (1999)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
M. Piccart-Gebhart (2005)
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
M. Pegram (2004)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
2 - Year follow - up of trastuzumab after adjuvant chemotherapy in HER 2 - positive breast cancer : a randomised controlled tri
I Smith (2007)
Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials
Wenjin Yin (2011)

This paper is referenced by
Targeted therapy for breast cancer in older patients.
N. Pondé (2019)
Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer
Ali Hajjar (2019)
Cancer cell selective probe by mimicking EGCG.
M. Kumazoe (2020)
Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis
P. Guo (2019)
Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades
Sarah DarbyWolfgang (2013)
The role of podocalyxin in breast cancer progression and metastasis
Kimberly Snyder (2014)
Cardiovascular complications of chemotherapy: A synopsis
L Steingo (2017)
Genome‐wide association study of genetic variants related to anthracycline‐induced cardiotoxicity in early breast cancer
Boram Park (2020)
Delay to Formalin Fixation (Cold Ischemia Time) Effect on Breast Cancer Molecules
T. Khoury (2018)
Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198)
B. Schneider (2015)
Adjuvant Therapy for HER2-Positive Early Breast Cancer
G. Basaran (2016)
Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data
H. W. Leung (2015)
Progress in adjuvant chemotherapy for breast cancer: an overview
Jesus D Anampa (2015)
PEGylation does not significantly change the initial intravenous or subcutaneous pharmacokinetics or lymphatic exposure of trastuzumab in rats but increases plasma clearance after subcutaneous administration.
Linda J. Chan (2015)
Identifying Driver Genes in Cancer by Triangulating Gene Expression, Gene Location, and Survival Data
Sigrid Rouam (2014)
Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology
P. Lancellotti (2017)
Using companion and coupled diagnostics within strategy to personalize targeted medicines.
D. Singer (2012)
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.
T. Vu (2014)
Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
A. Yu (2017)
Hybrid Imaging for Breast Malignancies
Federica Padovano (2019)
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).
H. Gómez (2016)
Tissue Banking, Bioinformatics, and Electronic Medical Records: The Front-End Requirements for Personalized Medicine
K. S. Suh (2013)
A Case of Trastuzumab-Associated Cardiomyopathy Presenting as an Acute Coronary Syndrome: Acute Trastuzumab Cardiotoxicity
Sylvana Hidalgo (2013)
Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer
C. Zhao (2019)
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.
E. D. Saad (2019)
Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes.
M. Burotto (2019)
Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab.
A. Banke (2019)
Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab
S. Sorscher (2013)
Targeted treatments of HER2-positive metastatic breast cancer: trastuzumab and beyond
D. Zardavas (2012)
Pharmacology and Clinical Development of New Molecularly Targeted Agents
E. Giovannetti (2015)
HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations
E. Nelson (2014)
Family history of breast and ovarian cancer and triple negative subtype in hispanic/latina women
K. Anderson (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar